Our current partners:
Airsonett is a Swedish research-based medical technology company which, with its unique technology, leads the way in the development of non-pharmaceutical treatment for allergic asthma. Airsonett offers Temperature controlled Laminar Airflow (TLA), which is a medical device intended as an add-on therapy for adults and children with severe persistent allergic asthma. This corresponds to patients who have reached Step 4 (BTS/SIGN) or above in the stepwise treatment approach and still have symptoms of uncontrolled disease.
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.
Innovative medicines for people and animals have for more than 130 years been what the research-driven pharmaceutical company Boehringer Ingelheim stands for. Boehringer Ingelheim is one of the pharmaceutical industry’s top 20 companies and to this day remains family-owned. Day by day, some 50,000 employees create value through innovation for the three business areas human pharmaceuticals, animal health and biopharmaceutical contract manufacturing.
EDT have teamed up with Asthma UK this year to help raise money to support Asthma UK’s work. Gary Rowney, Co-founder and Director of EDT said: “EDT operates within the automotive arena where our award winning product internally cleans engines which dramatically reduces emissions on both petrol and diesel vehicles. Both David Holmes, Managing Director, and myself, have had personal experiences with asthma to greater and lesser degrees, because of this we wanted to support the fantastic work that Asthma UK does; looking for new treatments and raising awareness of this often misunderstood and debilitating condition. We are making a contribution for every car that has an EDT treatment on it and are pleased that we have been able to persuade our partner garages to do the same.”
GlaxoSmithKline - one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer.
Napp Pharmaceuticals Limited is a UK healthcare company with a strong track record in bringing high-quality, innovative medicines to UK health professionals and their patients. Napp believe in excellence and delivering on our promises to the NHS, patients, our business partners and each other. Napp strive to offer new medicines and initiatives that meet genuine needs, make a positive difference to patients’ lives and support the NHS in delivering effective, high-quality, sustainable healthcare.
Novartis champions scientific research and innovation to help improve healthcare and reimagine medicine, both in the UK and around the world.
Orion is a Finnish-born, innovative European R&D-based pharmaceuticals and diagnostics company with an emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals and active pharmaceutical ingredients as well as diagnostic tests. Orion carries out extensive research with a goal of introducing new treatments into global markets. The core therapy areas in Orion’s product and research strategy are the central nervous system, oncology, critical care and respiratory medicines.
Roche is a global, research-focused healthcare company with Group Headquarters in Basel, Switzerland. Roche’s aim is to improve the health, quality of life and well-being of people around the world by providing an innovative range of diagnostic solutions and medicines.
Sanofi, a global healthcare leader, discovers, develops and distributes therapeutic solutions focused on patients' needs. Sanofi is organised into five global business units: Diabetes and Cardiovascular, General Medicines and Emerging Markets, Sanofi Genzyme, Sanofi Pasteur and Consumer Healthcare.
“At Teva, we help improve the health of over 200 million people every day. As the world’s largest generic medicines producer, we offer access to a medicine cabinet of more than 1,000 molecules, delivering a wide range of generic products to people in 100 countries. In specialty medicines, we have a world-leading position in several therapeutic areas, including the central nervous system and respiratory. We operate in 60 countries, producing 100 billion tablets every year. Our R&D pipeline, one of the richest in the industry, integrates generics and specialty capabilities to create new solutions for unmet patient needs, combining drug development with devices, services and technologies.”
Our partnership with Vax provides us with a platform to communicate key health advice messages directly to people with asthma. The partnership will ensure that people who purchase Vax air purifiers are given advice and support on steps they can take to reduce the impact of harmful triggers and prevent life-threatening asthma attacks.
We also have partnerships with:
- ALK - a global, research-driven pharmaceutical company that focuses on the prevention, diagnosis and treatment of allergies.
- Chiesi - an international pharmaceutical company, dedicated to the research, development and sales of innovative, therapeutic prescription medicines in the field of respiratory, neonatology, transplant medicine and rare diseases.
Are you interested in partnering with Asthma UK?
Call Victoria Copeland on 0207 786 5020 or email firstname.lastname@example.org for more information on how your organisation can get involved with Asthma UK.